Targeting Calcitonin Gene-Related Peptide and its Receptor by Monoclonal Antibody, New Developments in the Prevention of Migraine
DOI:
https://doi.org/10.17140/NOJ-2-e004Keywords:
Migraine; Calcitonin Gene Related Peptide (CGRP)Abstract
Migraine is a chronic headache disorder with an unknown pathophysiology. Research
in the past decade has shown that to be a brain disorder, a dismodulation of sensory processing
affecting vascular tone and pain1-3 but since the exact pathomechanism of migraine is not very
well known, its treatment is also difficult. Current drugs recommended by the “European Federation of Neurological Societies (EFNS)” used in the treatment of migraine include the triptan
family drugs that are serotonin (5-HT1B/D) receptor agonists, and the Non-Steroid Anti-Inflammatory Drugs (NSAIDs).4
Several other drugs such as anti-epileptic drugs, beta-blockers, and
calcium channel blockers are also recommended in the treatment of migraine.
References
Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med. 1995; 1: 658-660. doi: 10.1038/nm0795-658
Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12: 570- 584. doi: 10.1038/nrn3057
Cohen AS, Goadsby PJ. Functional neuroimaging of primary headache disorders. Expert Rev. Neurother. 2006; 6: 1159-1171. doi: 10.1586/14737175.6.8.1159
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009; 16: 968-981. doi: 10.1111/j.1468-1331.2009.02748.x
Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA, Tramu G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene related peptide immunoreactivities in the caudal trigeminal nucleus of the rat following electrical stimulation of the Gasserian ganglion: a possible co-release of neuropeptides. PAIN. 2000; 84: 389-395.
Friberg L, Olesen J, Olsen TS, Karle A, Ekman R, Fahrenkrug J. Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura. Cephalalgia. 1994; 14(1): 47-54. doi: 10.1046/j.1468-2982.1994.1401047.x
Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995; 15(5): 384-390. doi: 10.1046/j.1468-2982.1995.1505384.x
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cepha-lalgia. 2002; 22(1): 54-61. doi: 10.1046/j.1468-2982.2002.00310.x
Villalón CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009; 124: 309-323. doi: 10.1016/j.pharmthera.2009.09.003
Karsan N, Goadsby PJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep. 2015; 15(5): 25. doi: 10.1007/s11910-015-0547-z
Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Phar-macol. 2015; 80(2): 193-199. doi: 10.1111/bcp.12618
Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015; 79(6): 886-895. doi: 10.1111/bcp.12591
Tfelt-Hansen P, Olesen J. Possible site of action of CGRP antagonists in migraine. Cephalalgia. 2011; 31: 748-750. doi: 10.1177/0333102411398403
Humphrey PP. The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 2008; 48: 685-687. doi: 10.1111/j.1526-4610.2008.01097.x
Olesen J, Diener HC, Husstedt IW, et al. BIBN 4096 BS clinical proof of concept study group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350(11): 1104-1110. doi: 10.1056/ NEJMoa030505
Ho TW, Mannix LK, Fan X, et al. MK-0974 protocol 004 study group. Collaborators (20), randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312.
Connor K.M, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977. doi: 10.1212/WNL.0b013e3181b87942
Iovino M, Feifel U, Yong CL, Wolters JM, Wallenstein G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia. 2004; 24: 645-656. doi: 10.1111/j.1468-2982.2004.00726.x
Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123. doi: 10.1016/S0140-6736(08)61626-8
Samsam M, Coveñas R, Ahangari R, Yajeya J. Neuropeptides and other chemical mediators, and the role of anti-inflammatory drugs in primary headaches. AIAA-MC. 2010; 3: 170-188. doi: 10.2174/1871523011009030170
Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J. BI44370TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011; 31(5): 573-584.
Salvatore CA, Moore EL, Calamari A, et al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010; 333: 152-160. doi: 10.1124/jpet.109.163816
Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011; 31: 712-722. doi: 10.1177/0333102411398399
Leahy DK, Fan Y, Desai LV, et al. Efficient and scalable enantioselective synthesis of a CGRP antagonist. Org Lett. 2012; 14: 4938-4941. doi: 10.1021/ol302262q
Luo G, Chen L, Conway CM, et al. Discovery of BMS-846372, a potent and orally active human CGRP receptor antagonist for the treatment of migraine. ACS Med Chem Lett. 2012; 3: 337-341. doi: 10.1021/ml300021s
Merck Sharp & Dohme Corp. A pharmacokinetic study of MK-1602 in the treatment of acute migraine (MK-1602-007). Web-site: https://clinicaltrials.gov/ct2/show/NCT01657370 2012; Accessed January 2015.
Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs. 2010; 24: 539-548. doi: 10.2165/11534920-000000000-00000
Poyner DR, Sexton PM, Marshall I, et al. Foord SM. International union of pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002; 54: 233-246.
Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014; 28(5): 389-399. doi: 10.1007/s40263-014-0156-4
Reuter U. Anti-CGRP antibodies: a new approach to migraine prevention. Lancet Neurol. 2014; 13(9): 857-859. doi: 10.1016/ S1474-4422(14)70126-7
Samsam M. Drugs against calcitonin gene-related peptide and its receptor used in the treatment of migraine: what are the new progresses? Neuro Open J. 2015; 2: 79-91.
Eli Lilly and Company. CGRP mAb migraine prevention Website: http://www.lilly.com/SiteCollectionDocuments/Pipeline/ Clinical%20Development%20Pipeline/10.html 2015; Accessed August, 2015.
Alder Biopharmaceuticals Inc. A parallel group, double-blind, randomized, placebo controlled dose-ranging phase 2 trial to evaluate the efficacy, safety, and pharmacokinetics of ALD403 administered intravenously in patients with chronic migraine. Web-site: http://www.alderbio.com/clinical-trials/ 2015; Accessed August, 2015.
Teva Pharmaceuticals. Teva to present new findings at the American Headache Society (AHS) Meeting-analysis of migraine phase IIb studies provides novel insights into TEV-48125 efficacy and safety in both episodic & chronic migraine. Website: http:// news.tevausa.com/mobile.view?c=251945&v=203&d=1&id=2060482 2015; Accessed August, 2015.
Amgen. Amgen to present AMG 334 data at 17th congress of the international headache society: data evaluating safety and efficacy of AMG 334 provides new insights into preventive treatment of migraine. Website: http://wwwext.amgen.com/media/me-dia_pr_detail.jsp?year=2015&releaseID=2046668 2015; Accessed August, 2015.
Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014; 13(9): 885-892. doi: 10.1016/S1474-4422(14)70128-0
Dodick DW, Goadsby PJ, Silberstein SD, et al. ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014; 13(11): 1100-1107. doi: 10.1016/S1474-4422(14)70209-1
Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia. 2013; 34(7): 483-492. doi: 10.1177/0333102413517775
PRNewswire/THOUSAND OAKS, Calif. Amgen presents open-label extension data from ongoing phase 2 study of AMG 334 in the prevention of episodic migraine: http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=2061044 2015; Accessed June 19, 2015.
Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev. 1999; 51: 159-212.
Nakanishi M, Hata K, Nagayama T, et al. Acid activation of Trpv1 leads to an up-regulation of calcitonin gene-related peptide expression in dorsal root ganglion neurons via the CaMK-CREB cascade: a potential mechanism of inflammatory pain. Mol Biol Cell. 2010; 21(15): 2568-2577. doi: 10.1091/mbc.E10-01-0049
Szallasi A, Sheta M. Targeting TRPV1 for pain relief: limits, losers and laurels. Expert Opin Investig Drugs. 2012; 21: 1351- 1369. doi: 10.1517/13543784.2012.704021
Kaneko Y, Szallasi A. Transient receptor potential (TRP) channels: a clinical perspective. Br J Pharmacol. 2014; 171: 2474- 2507. doi: 10.1111/bph.12414
Riera CE, Huising MO, Follett P, et al. TRPV1 pain receptors regulate longevity and metabolism by neuropeptide signaling. Cell. 2014; 157(5): 1023-1036. doi: 10.1016/j.cell.2014.03.051
Hoffmann J, Goadsby PJ. Emerging targets in migraine. CNS Drugs. 2014; 28: 11-17. doi: 10.1007/s40263-013-0126-2
Diener HC, Charles A, Goadsby PJ, et al. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015; 14: 1010-1022. doi: 10.1016/S1474-4422(15)00198-2
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Neuro (NEURO) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.